Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
NCT01416181 · Biogen · PHASE3 · terminated · last registry update 2017-09-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-09-04Phase 3 first posted: Millennium Pharmaceuticals, Inc., Vedolizumab Placebo + Vedolizumab (NCT03657160)
- 2018-06-15Results posted on the registry: Johns Hopkins University, a drug against ITGA4 (NCT02846558)
- 2018-05-14Also stopped (withdrawn): Universita degli Studi di Genova, vedolizumab (NCT02820493)
- 2017-09-06Results posted on the registry: University of Chicago, Tysabri (NCT01071512)
- 2017-07-31Phase 3 first posted: Takeda, Vedolizumab IV + Placebo (NCT03234907)
- 2017-07-18Phase 3 first posted: Takeda, Vedolizumab IV + Placebo (NCT03221036)
- 2017-06-09Results posted on the registry: Biogen, natalizumab + fingolimod (NCT02342704)
- 2017-06-09Also stopped (terminated): Biogen, natalizumab + fingolimod (NCT02342704)
- 2017-06-05Results posted on the registry: Biogen, natalizumab (NCT02241785)
- 2017-06-05Also stopped (terminated): Biogen, natalizumab (NCT02241785)
- 2017-03-31Results posted on the registry: University of South Florida, Tysabri ® (Natalizumab) (NCT01455220)
- 2017-03-08Also stopped (withdrawn): Takeda, Vedolizumab + Placebo (NCT03035058)
- 2017-02-01Results posted on the registry: Takeda, Vedolizumab SC + Vedolizumab IV (NCT02163421)
- 2017-01-27Phase 3 first posted: Takeda, Vedolizumab + Placebo (NCT03035058)
- 2016-12-29Also stopped (withdrawn): University of Texas Southwestern Medical Center, methylprednisolone (NCT01710228)
- 2016-11-03Phase 3 first posted: Medical College of Wisconsin, Tacrolimus + Vedolizumab (NCT02954159)
- 2016-09-23Also stopped (withdrawn): Takeda, Vedolizumab intravenous injection + Vedolizumab subcutaneous injection (NCT02913508)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision